TransMedics Group, Inc.
TMDX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2,072 | $2,567 | $1,824 | $529 |
| - Cash | $337 | $395 | $201 | $26 |
| + Debt | $518 | $516 | $68 | $44 |
| Enterprise Value | $2,254 | $2,688 | $1,691 | $547 |
| Revenue | $442 | $242 | $93 | $30 |
| % Growth | 82.7% | 158.5% | 208.8% | – |
| Gross Profit | $262 | $154 | $65 | $21 |
| % Margin | 59.4% | 63.8% | 69.8% | 69.9% |
| EBITDA | $70 | -$8 | -$29 | -$38 |
| % Margin | 15.8% | -3.2% | -31% | -127.2% |
| Net Income | $35 | -$25 | -$36 | -$44 |
| % Margin | 8% | -10.4% | -38.8% | -146.1% |
| EPS Diluted | 1.01 | -0.77 | -1.23 | -1.6 |
| % Growth | 231.2% | 37.4% | 23.1% | – |
| Operating Cash Flow | $49 | -$13 | -$46 | -$29 |
| Capital Expenditures | -$130 | -$179 | -$12 | -$4 |
| Free Cash Flow | -$81 | -$192 | -$58 | -$32 |